Browse the evidence

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

New treatment approaches, including glucagon-like peptide-1 agonists, may be effective for weight loss in pregnant individuals.

Healthcare providers should consider new medical therapies for managing obesity in pregnant individuals.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

A statistically lower proportion of patients in the compounded Semaglutide group (71.61%) reported at least one side effect compared to the pure Semaglutide group (77.40%).

Practitioners may consider that compounded Semaglutide is associated with a lower incidence of side effects.

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

Obesity increases the risk of hypertension and other cardiometabolic comorbidities.

Practitioners should be aware of the increased risk of hypertension in obese patients.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

High sodium intake above 4,000 mg/d leads to a linear increase in mean arterial pressure (MAP).

Practitioners should be aware that high sodium intake can significantly affect blood pressure.

Sodium intake below 1,200 mg/d cannot maintain homeostasis.

Practitioners should recognize that insufficient sodium intake can lead to physiological imbalances.

Serum hepatocyte growth factor (HGF) increased at T4, indicating its role in muscle satellite cell activation.

Increased HGF levels post-exercise may be leveraged to enhance muscle recovery strategies.

The pattern of protein ingestion altered blood amino acid (AA) and insulin profiles.

Different protein ingestion patterns may optimize hormonal responses post-exercise.

Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.

Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.

Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).

Semaglutide may help lower leptin levels, which could be beneficial for weight management in diabetic patients.

Adiponectin levels increase significantly post-semaglutide add-on therapy, with the greatest increase in the obesity group (+3.70 μg/mL).

Increased adiponectin levels with semaglutide may enhance metabolic health in diabetic patients.

Long-term mortality was significantly lower in the GLP-1 group (odds ratio 0.58, 95% CI 0.36-0.94).

GLP-1 receptor agonists may improve long-term survival in patients undergoing endovascular treatment for aneurysms.

Obesity is associated with menstrual irregularities, poorer reproductive and obstetric outcomes, and an increased risk of endometrial cancer.

Clinicians should be aware of the reproductive health risks associated with obesity in women.

Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.

Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.

Effective weight loss, even when accompanied by gastrointestinal side effects, was associated with a greater willingness to continue Ozempic treatment.

Practitioners should emphasize the importance of weight loss effectiveness in encouraging patients to continue treatment despite side effects.

Semaglutide offers robust cardiovascular protection.

Clinicians can consider semaglutide for patients needing cardiovascular protection in obesity management.